# VERIFY: Vedolizumab for the Prevention of Immune Checkpoint Inhibitor Related Diarrhea or Colitis in Patients With Cancer

> **NCT06337695** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **University of Calgary** · enrollment: 298 (estimated)

## Conditions studied

- Cancer
- Cancer Metastatic

## Interventions

- **BIOLOGICAL:** Vedolizumab
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT06337695
- **Lead sponsor:** University of Calgary
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-07-01
- **Primary completion:** 2026-11-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 298 (ESTIMATED)
- **Last updated:** 2024-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06337695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06337695, "VERIFY: Vedolizumab for the Prevention of Immune Checkpoint Inhibitor Related Diarrhea or Colitis in Patients With Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06337695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*